Amgen shelves early-stage bispecific T cell engager
Amgen has stopped development of a Phase 1 bispecific T cell engager, a type of medicine that is core to its oncology portfolio and for which it has trademarked the BiTE acronym. The California...
View ArticleArcutis tacks on atopic dermatitis approval for Zoryve cream
The FDA approved Arcutis Biotherapeutics’ skin treatment Zoryve to treat mild to moderate atopic dermatitis in adults and some children, the company announced Tuesday. It’s the drug’s third approval in...
View ArticleClik here to view.
'Next-gen' biotech acquirers find M&A momentum in Q2
Is it prime time for the “next-gen” biopharma acquirers? The headlines have flourished since April. Genmab and Ono Pharmaceutical made their first acquisitions. Vertex inked its largest M&A deal...
View ArticleFlagship raises $3.6B for 25 new startups
Flagship Pioneering, the 25-year-old life sciences incubator and investor, has reeled in $3.6 billion to build another 25 or so companies, it said Wednesday morning. The new capital pool consists of...
View ArticleBiotech salary analysis: The best and worst paying biopharmas of 2023
The typical biopharma worker made $199,048 last year, according to an Endpoints News annual analysis of pay trends. Endpoints reviewed regulatory filings from hundreds of drugmakers and life sciences...
View ArticleHow the world's biggest pharma and biotech companies paid their typical...
Among the biopharma industry’s biggest employers, California’s Gilead Sciences had the highest median salary for its workforce, an Endpoints News analysis found. Endpoints tallied 2023 median employee...
View ArticleThe best-paying biotechs in the Bay Area, Boston and San Diego for 2023
As part of our analysis of CEO and employee pay in biopharma, Endpoints News analyzed median employee pay in 2023 at 177 life sciences companies. Sixty of the top 100 highest-paying companies were...
View ArticleIdeaya aims to raise $263M; Immuneel extends Series A with $12M
Plus, news about XyloCor, Pfizer, Evotech, Skyhawk Therapeutics, HepaRegeniX and Vyome: Ideaya Biosciences’ $263M public offering: The South San Francisco, CA-based biotech said Tuesday it will sell...
View ArticleCEO Noubar Afeyan on how Flagship’s newest fund could shape biotech’s future
Flagship Pioneering is known for creating startups that aim to answer broad scientific questions in medicine, sustainability and agriculture, a strategy it describes as “leaps.” On Wednesday, Flagship...
View ArticleClik here to view.
Researchers discover a hormone in mouse mothers that helps build bone
Scientists have discovered a hormone responsible for keeping bones sturdy in lactating people and mice, which could have broad applications for treating bone conditions like osteoporosis and gum...
View ArticleHouse committee raises concerns on CDER-CBER misalignment amid 2025 funding...
The House Appropriations Committee on Wednesday began marking up the FDA’s 2025 funding bill, offering the agency about 1% less than 2024 and almost 10% less than what President Joe Biden requested....
View ArticleClik here to view.
AbbVie CSO Tom Hudson to retire, replaced by medical chief
A day after Pfizer disclosed the departure of its longtime chief scientific officer, AbbVie is doing the same, announcing that research chief Tom Hudson is retiring. Roopal Thakkar Replacing Hudson is...
View ArticleThermo Fisher closes $3.1B Olink acquisition after UK antitrust review is...
Life sciences giant Thermo Fisher on Wednesday closed its $3.1 billion deal for Olink, adding protein analysis to its drug discovery tools in a move that’s likely to boost the growing proteomics...
View ArticleCMS rolls out policy proposals on non-opioid drugs, radiopharmaceuticals —...
The Centers for Medicare & Medicaid Services on Wednesday outlined a series of proposed policy changes for next year that would change the way non-opioid drugs and certain radiopharmaceutical...
View ArticleNovo-partnered Aspect Biosystems gets $70M+ cash injection from Canadian...
Aspect Biosystems has received $72.75 million in funding from the governments of Canada and British Columbia to advance its pipeline of preclinical 3D-printed tissue candidates. The Vancouver-based...
View ArticleClik here to view.
Almost all patients quit weight loss shots within two years, analysis finds
Only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. The findings could make...
View ArticleNovartis to shut down San Diego technical research and development facility
In an effort to “evolve” its global development organization, Novartis is set to exit a technical research and development site in San Diego, the Swiss pharma confirmed to Endpoints News. The “phased...
View ArticleFDA rejects Novo Nordisk’s once-weekly insulin, questions manufacturing and...
Novo Nordisk’s once-weekly insulin has been turned down by the FDA, and the Danish pharma likely won’t be refiling until next year. The FDA rejection comes after the EU, Canada, Australia, Japan and...
View ArticleIpsen takes on another ADC, this time from Foreseen Biotechnology
Ipsen is adding a second antibody-drug conjugate to its plate. The French drugmaker said Thursday that it has inked a global licensing agreement for a preclinical ADC developed by Foreseen...
View ArticleClik here to view.
Pfizer's once-daily oral GLP-1 drug passes first clinical tests
Pfizer is making a move on its obesity pipeline after multiple quarters of questions from investors and analysts. The New York pharma giant said Thursday it will move a once-daily, modified release...
View Article